Comparative Pharmacology
Head-to-head clinical analysis: NICORETTE MINT versus NICOTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICORETTE MINT versus NICOTINE.
NICORETTE (MINT) vs NICOTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine binds to nicotinic acetylcholine receptors (nAChRs) in the brain, stimulating dopamine release in the mesolimbic pathway, which reduces withdrawal symptoms and cravings associated with smoking cessation.
Nicotine is a nicotinic acetylcholine receptor (nAChR) agonist; binds to α4β2 and α7 subtypes in the central nervous system, causing release of dopamine and other neurotransmitters, leading to stimulation and reward effects. Also acts on peripheral nicotinic receptors affecting autonomic ganglia, neuromuscular junction, and adrenal medulla.
For smoking cessation, apply one 2 mg or 4 mg lozenge (mint) every 1-2 hours as needed for cravings, up to 15 lozenges per day. Use 4 mg lozenge if first cigarette is within 30 minutes of waking. Do not chew; allow to dissolve slowly (20-30 minutes). Frequency should be tapered after 6 weeks.
Transdermal patch: 21 mg/24 hours applied to dry, non-hairy skin once daily; gum: 2-4 mg chewed as needed (max 24 pieces/day); lozenge: 2-4 mg dissolved as needed (max 20 lozenges/day); inhaler: 6-16 cartridges/day (each 4 mg delivered); nasal spray: 1-2 doses/hour (1 dose = 0.5 mg, 32 mg/day max).
None Documented
None Documented
2 hours (range 1-4) for nicotine; terminal half-life 10-12 hours for cotinine; clinical context: short t½ requires frequent dosing. Half-life prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); short half-life leads to frequent dosing to maintain therapeutic effects.
Renal: 60-80% as metabolites (cotinine, nicotine N-oxide), 10-20% unchanged; biliary/fecal: <10%
Primarily hepatic metabolism (80-90%) to cotinine and nicotine-N-oxide; renal excretion of unchanged nicotine accounts for 5-10% in non-smokers and up to 30% in smokers with acidic urine; less than 2% excreted in feces via biliary elimination.
Category C
Category C
Smoking cessation aid
Smoking cessation aid